At 12 months, the HF hospitalization and stroke were similarly significantly lower in the SGLT2 inhibitor user group, in addition to lower AF incidence [1 (0.3%) vs. 3 (2.7%), p-value = 0.045]. This evidence concerns the gene SLC5A2 and Stroke.